Big Changes and Small Moves for Teva Pharmaceutical Industries Ltd.

Teva Pharmaceuticals (NYSE: TEVA  ) has been engulfed with turmoil. Its blockbuster MS franchise is facing a new competitive thereat, and the company is staring down the barrel of its patent expiration. Then in October, we saw the surprise departure of still-new-on-the-job CEO Jeremy Levin.

Teva has not stood still. This past week has seen the company jump into the bidding for NuPathe (UNKNOWN: PATH.DL  ) , topping Endo Health's (NASDAQ: ENDP  ) offer for the former's FDA-approved migraine patch. More importantly, it filled the vacancy in its CEO suite. Board member Erez Vigodman is set to take over, and has been hailed as an excellent choice, but he has a challenging road ahead.

In this video Motley Fool health-care analyst David Williamson discusses the competing NuPathe deals and what they mean for investors in both stocks, as well as the challenges Teva's new CEO will face and the important questions he must answer.

Our top stock for 2014
There's a huge difference between a good stock, and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2792217, ~/Articles/ArticleHandler.aspx, 9/2/2015 10:54:00 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

David Williamson

The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...

Today's Market

updated 1 hour ago Sponsored by:
DOW 16,351.38 293.03 1.82%
S&P 500 1,948.86 35.01 1.83%
NASD 4,749.98 113.87 2.46%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/2/2015 3:59 PM
ENDP $74.96 Up +1.48 +2.01%
Endo International CAPS Rating: ***
PATH.DL $0.00 Down +0.00 +0.00%
NuPathe Inc. CAPS Rating: *
TEVA $64.84 Up +1.66 +2.63%
Teva Pharmaceutica… CAPS Rating: *****